[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"indeterminate-lesions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:indeterminate-lesions":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100516681","phase-3-a-phase-3-randomized-masked-controlled-trial-to-evaluate-efficacy-and-safety-of-belzupacap-sarotalocan-au-011-treatment-compared-to-sham-control-in-subjects-with-primary-indeterminate-lesions-or-small-choroidal-melanoma-100516681",false,"NCT06007690","A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","CoMpass","Inclusion Criteria:\n\n* Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL\u002FCM)\n* Have no evidence of metastatic disease confirmed by imaging\n* Be treatment naive for IL\u002FCM (subjects who received PDT may be eligible)\n\nExclusion Criteria:\n\n* Have known contraindications or sensitivities to the study drug or laser\n* Active ocular infection or disease","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).",[26,27,28,29],"Choroidal Melanoma","Indeterminate Lesions","Uveal Melanoma","Ocular Melanoma",[28,31,29,26],"Eye Cancer","RECRUITING","2026-02-26",{"date":35,"type":36},"2026-03-02","ACTUAL",{"date":38,"type":36},"2023-12-06",{"date":40,"type":20},"2028-08-15",{"name":42,"class":43},"Aura Biosciences","INDUSTRY",71,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":63,"locationsCount":64},"100625369","choroidal-melanoma-patient-reported-outcome-study-cm-pro-in-a-subset-of-au-011-301-compass-subjects-100625369","NCT07421739","Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects","Inclusion Criteria:\n\n* Have enrolled in the Aura-sponsored clinical trial AU-011-301.\n* Access to a connected device (i.e., smartphone, laptop, or tablet)\n\nExclusion Criteria:\n\n* None",{"count":52,"type":20},15,"OBSERVATIONAL","To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.",[26,27,28,29],[28,31,29,26],"2026-02-17",{"date":59,"type":36},"2026-02-19",{"date":61,"type":36},"2025-11-12",{"date":40,"type":20},{"name":42,"class":43},1,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":14,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100619003","a-long-term-follow-up-study-of-subjects-completing-the-au-011-301compass-for-early-choroidal-melanoma-100619003","NCT07338968","A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma","A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions\u002FSmall Choroidal Melanomas)","Inclusion Criteria:\n\n* Have received bel-sar or sham treatment in the Aura-sponsored clinical trial AU-011-301.\n* Be willing and able to consent to the AU-011-403 study.\n\nExclusion Criteria:\n\n* None",{"count":19,"type":20},"AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up study",[26,27],[29,76],"Small Choroidal Melanoma","NOT_YET_RECRUITING","2026-01-07",{"date":80,"type":36},"2026-01-14",{"date":82,"type":20},"2026-02-01",{"date":84,"type":20},"2033-08-15",{"name":42,"class":43}]